Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,227,953
  • Shares Outstanding, K 157,787
  • Annual Sales, $ 1,171 M
  • Annual Income, $ -196,620 K
  • 60-Month Beta 1.67
  • Price/Sales 1.89
  • Price/Cash Flow 24.11
  • Price/Book 2.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.28
  • Number of Estimates 4
  • High Estimate -0.15
  • Low Estimate -0.37
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +15.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.98 +22.79%
on 03/18/20
18.32 -19.71%
on 03/09/20
-4.28 (-22.54%)
since 03/06/20
3-Month
11.98 +22.79%
on 03/18/20
21.46 -31.45%
on 03/03/20
-4.74 (-24.37%)
since 01/06/20
52-Week
11.98 +22.79%
on 03/18/20
37.75 -61.03%
on 04/09/19
-22.45 (-60.41%)
since 04/05/19

Most Recent Stories

More News
First Week of ALKS November 20th Options Trading

Investors in Alkermes plc saw new options begin trading this week, for the November 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value,...

ALKS : 14.66 (+3.82%)
Shares of Alkermes Plc Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (ALKS , HRTX , IRWD , ICPT , BLUE )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ALKS : 14.66 (+3.82%)
HRTX : 12.46 (+6.59%)
IRWD : 9.83 (-0.41%)
Alkermes (ALKS) Down 8.6% Since Last Earnings Report: Can It Rebound?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALKS : 14.66 (+3.82%)
SmarTrend Watching for Potential Rebound in Shares of Alkermes Plc After 8.38% Loss

Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $16.16 to a high of $17.43. Yesterday, the shares fell 8.4%, which took the trading range below the 3-day low of $16.39...

ALKS : 14.66 (+3.82%)
Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia

Alkermes plc (Nasdaq: ALKS) today announced the publication of results from the phase 3 ENLIGHTEN-1 clinical trial of ALKS 3831 (olanzapine/samidorphan) in the peer-reviewed publication, Journal of Clinical...

ALKS : 14.66 (+3.82%)
Global Stress Management Industry Report - Featuring Abbott Laboratories, Alkermes & Allergan Among Others

The "Stress Management Industry: Global Trends" report has been added to ResearchAndMarkets.com's offering.

ABT : 82.15 (+3.40%)
ALKS : 14.66 (+3.82%)
AGN : 176.96 (+0.71%)
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 at 3:30 p.m....

ALKS : 14.66 (+3.82%)
Alkermes Plc has the Best Relative Performance in the Biotechnology Industry (ALKS , AKBA , CLVS , ARDX , BLUE )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

AKBA : 6.87 (+2.08%)
ALKS : 14.66 (+3.82%)
CLVS : 6.80 (+11.48%)
SmarTrend Watching for Potential Pullback in Shares of Alkermes Plc After 5.30% Gain

Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $18.70 to a high of $19.75. Yesterday, the shares gained 5.3%, which took the trading range above the 3-day high of $18.82...

ALKS : 14.66 (+3.82%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CLVS , ALKS , PBYI , AKBA , AMAG )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ALKS : 14.66 (+3.82%)
CLVS : 6.80 (+11.48%)
PBYI : 7.68 (+9.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ALKS with:

Business Summary

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication...

See More

Key Turning Points

2nd Resistance Point 14.63
1st Resistance Point 14.37
Last Price 14.71
1st Support Level 13.84
2nd Support Level 13.57

See More

52-Week High 37.75
Fibonacci 61.8% 27.91
Fibonacci 50% 24.86
Fibonacci 38.2% 21.82
Last Price 14.71
52-Week Low 11.98

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar